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Abstract: The advent of potent antiplatelet and antithrombotic agents over the past decade has 
resulted in significant improvement in reducing ischemic events in acute coronary syndrome 
(ACS). However, the use of antiplatelet and antithrombotic combination therapy, often in the 
settings of percutaneous coronary intervention (PCI), has led to an increase in the risk of bleed-
ing. In patients with non-ST elevation myocardial infarction treated with antithrombotic agents, 
bleeding has been reported to occur in 0.4%–10% of patients, whereas in patients undergoing 
PCI, periprocedural bleeding occurs in 2.2%–14% of cases. Until recently, bleeding was con-
sidered an intrinsic risk of antithrombotic therapy, and efforts to reduce bleeding have received 
little attention. There have been increasing data demonstrating that bleeding is associated with 
adverse outcomes, including myocardial infarction, stroke, and death. Therefore, it is imperative 
to optimize patient outcomes by adopting pharmacological and nonpharmacological strategies 
to minimize bleeding while maximizing treatment efficacy. In this paper, we present a review 
of the bleeding classifications used in large-scale clinical trials in patients with ACS and those 
undergoing PCI treated with antiplatelets and antithrombotic agents, adverse outcomes, particu-
larly mortality associated with bleeding complications, and suggested predictive risk factors. 
Potential mechanisms of the association between bleeding and mortality and strategies to reduce 
bleeding complications are also discussed.
Keywords: bleeding risk, antiplatelets, antithrombotics, acute coronary syndrome,   percutaneous 
coronary intervention
Bleeding classifications: historical perspectives
The TIMI and GUSTO scales were the first bleeding classifications developed to 
measure short-term bleeding associated with thrombolytic therapy in patients with ST 
elevation myocardial infarction (STEMI). The TIMI classification was a laboratory-
based scale that categorized bleeding as major or minor.1 Major bleeding was defined 
as any intracranial bleeding or a reduction in hemoglobin of 5 g/dL (or a .15% 
decrease in hematocrit). Minor bleeding was defined by an observed blood loss and a 
drop in hemoglobin of 3–5 g/dL (or in hematocrit of 10%–15%), spontaneous gross 
hematuria or hematemesis (.120 mL), even if the hemoglobin or hematocrit drop 
was 3 g or 10%, respectively, or an unobserved loss of 4 g/dL in hemoglobin 
or 12% in hematocrit.
The GUSTO classification was based on clinical events that classified bleeding as 
severe/life-threatening, moderate, or mild.2 Severe bleeding was defined as intracranial 
bleeding or bleeding which resulted in substantial hemodynamic compromise requir-
ing intervention. Moderate bleeding was defined by the need for blood transfusion Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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but without hemodynamic insult, and minor bleeding was 
defined by bleeding which did not require transfusion or 
cause hemodynamic instability.
With the advent of more potent antithrombotic agents 
and American College of Cardiology/American Heart Asso-
ciation guidelines for long-term oral antiplatelet therapy in 
patients with acute coronary syndrome (ACS) and those 
undergoing percutaneous coronary intervention (PCI), the 
TIMI and GUSTO scales may have limited applicability 
to current clinical trials. It should be noted that the TIMI 
definition was developed to quantify bleeding complications 
in patients receiving thrombolytic therapy for STEMI and 
may underestimate the impact of bleeding complications on 
mortality in patients undergoing planned or urgent PCI. Due 
to the limitations of these scales, over the last half decade 
clinical investigators have devised study-specific bleeding 
definitions to assess patients’ risks and outcomes, such as 
those defined by the ACUITY and REPLACE-2 trials (dis-
cussed below).3,4
Noncoronary artery bypass graft (CABG) ACUITY-scale 
major bleeding was defined as intracranial or intraocular 
bleeding, access site hemorrhage requiring intervention, 
hematoma 5 cm in diameter, reduction in hemoglobin of 
3 g/dL with an overt source of bleeding or 4 g/dL and no 
source identified, reoperation for bleeding, or blood product 
transfusion. Analysis of the ACUITY trial demonstrated that 
major bleeding is a powerful predictor of 30-day mortality 
in patients with ACS managed invasively (odds ratio [OR] 
7.55, P  0.0001). Independent predictors of major bleeding 
were advanced age, female gender, diabetes, hypertension, 
renal insufficiency, anemia, no prior PCI, cardiac biomarker 
elevation, ST segment elevation 1 mm, and treatment with 
heparin plus glycoprotein IIb/IIIa inhibitor (GPI) versus 
bivalirudin monotherapy.
The REPLACE-2 trial classified bleeding as major and 
minor based on both adverse clinical events and labora-
tory values. Major hemorrhage was defined as intracranial, 
intraocular, or retroperitoneal, overt blood loss with a .3 g/dL 
decrease in hemoglobin, any hemoglobin decrease .4 g/dL, 
or transfusion of 2 units of blood products. Minor hemor-
rhage was defined as overt bleeding that did not meet the 
criteria for major bleeding. Major hemorrhage as defined 
by the REPLACE-2 study protocol was found to be an 
independent predictor of mortality in patients undergoing 
elective or urgent PCI. Independent baseline predictors of 
major hemorrhage included advanced age, female gender, 
impaired creatinine clearance, and anemia (defined using 
World Health Organization criteria of hemoglobin 13 g/dL 
in men and 12 g/dL in women) whereas independent 
periprocedural predictive factors included treatment with 
heparin plus GPI, increased procedural duration, provisional 
use of GPI, increased time to sheath removal, length of 
intensive care unit stay, and use of an intra-aortic balloon 
pump (all P  0.05).5
Until recently, there has been no consensus on the end-
point definitions of bleeding in patients with ACS or those 
undergoing PCI. In February 2010, the Bleeding Academic 
Research Consortium consisting of leaders in the field 
of cardiovascular disease and experts from the academic 
research organizations, the Food and Drug Administration, 
the National Institutes of Health, and the pharmaceutical and 
cardiovascular device manufacturers set forth a standardized 
Bleeding Academic Research Consortium definition of bleed-
ing. The proposed bleeding definition consisted of five types, 
from 0 to 5. Type 0 was defined as no evidence of bleeding. 
Type 1 was defined as bleeding which is not actionable and 
does not cause the patient to seek unscheduled performance 
of studies, hospitalization, or treatment by a health care pro-
fessional. Type 2 was defined as any clinically overt sign of 
hemorrhage that is actionable but does not meet criteria for 
type 3, type 4 (CABG-related), or type 5 (fatal bleeding). The 
bleeding must require diagnostic studies, hospitalization, or 
treatment by a health care professional. Type 3 was defined 
as clinical, laboratory, and/or imaging evidence of bleeding 
with specific health care provider responses. Type 4 was 
defined as CABG-related bleeding and type 5 was defined 
as fatal bleeding. It is noteworthy that the proposed bleed-
ing definitions were based on expert consensus rather than 
clinical data. Validation of the consensus definitions is still 
needed from future cardiovascular clinical trials.6,7
Currently, the American College of Cardiology task 
force on clinical data standards recommends using the 
TIMI classification as the standard for classifying bleeding 
events. Nonetheless, in a pooled analysis of the PURSUIT 
(n = 10,798) and PARAGON B (n = 5225) trials to determine 
the association between the severity of TIMI and GUSTO 
bleeding and 30-day and six-month death or myocardial 
infarction, Rao et al demonstrated that while both GUSTO 
and TIMI bleeding scales identified patients at risk for 
adverse outcomes, when both bleeding definitions were 
included in the same model, the stepwise increase in the 
risk with worsening GUSTO bleeding persisted, whereas 
the association between any level of TIMI bleeding and 
outcome was no longer significant.8 The results of the study 
suggested that clinically evident bleeding added prognostic 
value to laboratory parameters.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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In summary, bleeding classification appears to have a 
better prognostic value when both clinical and laboratory 
data are incorporated. It has generally been accepted that 
any significant bleeding episode involves intracranial or 
intraocular bleeding, hemodynamic compromise requiring 
blood transfusions, observed blood loss with a hemoglobin 
drop of at least 3 g/dL, or access site complications requiring 
surgical intervention.
The Bleeding Academic Research Consortium definitions 
of bleeding are summarized in Table 1. The definitions of 
major bleeding in large-scale clinical trials (discussed in this 
article) are summarized in Table 2.
Adverse outcomes associated  
with bleeding in ACS and PCI
Bleeding is an important safety concern for patients with ACS 
and those undergoing PCI who are managed with multiple 
antithrombotic agents. The effect of bleeding was thought 
to be acute, and when treated accordingly, had no long-term 
impact. However, over the last half decade, there has been 
increasing evidence demonstrating an association between 
bleeding and short-term and long-term adverse cardiovas-
cular events, most importantly, mortality. An overview of 
the literature on the impact of bleeding on short-term and 
long-term outcomes, particularly mortality in patients with 
ACS and those undergoing PCI, is presented followed by a 
brief discussion of the authors’perspectives.
Rao et al were among the first to report the associa-
tion between bleeding and mortality. In a meta-analysis of 
four multicenter, randomized clinical trials to determine 
the association between bleeding severity as measured 
by the GUSTO scale and mortality rates in patients with 
NSTEMI-ACS, Rao et al demonstrated stepwise increases 
in 30-day and six-month mortality as bleeding severity 
increased.9 Clinical data were obtained from the GUSTO 
IIb (n = 8011), PURSUIT (n = 10,948), and PARAGON A 
and B (n = 2282 and n = 5225, respectively) trials. Of more 
than 26,000 patients studied, 27.6% had at least one bleed-
ing event during the index hospitalization. The proportions 
of patients with mild, moderate, and severe bleeding were 
16.6%, 9.8%, and 1.2%, respectively. Older age, female 
gender, the presence of cardiac risk factors, inhospital treat-
ment with hirudin, eptifibatide, or lamifiban, and the need 
for invasive cardiac procedures were seen more frequently 
in patients who had a bleeding event compared with those 
who did not (P  0.001). There were stepwise increases in 
the adjusted hazards of 30-day and six-month mortality as 
bleeding severity increased (hazards ratio [HR] for 30-day 
mortality categorized by bleeding severity were 1.6 [1.3–1.9], 
2.7 [2.3–3.4], and 10.6 [8.3–13.6] for mild, moderate, and 
Table 1 Bleeding Academic Research Consortium bleeding definitions
Type 0 No bleeding
Type 1    Bleeding that is not actionable and does not cause the patient to seek unscheduled performance of studies, hospitalization, or treatment by 
a health care professional; may include episodes leading to self-discontinuation of medical therapy by the patient without consulting a health 
care professional 
Type 2    Any overt, actionable sign of bleeding (eg, more bleeding than would be expected for a clinical circumstance, including bleeding found by 
imaging alone) that does not fit the criteria for type 3, 4, or 5 but does meet at least one of the following criteria: requiring nonsurgical, 
medical intervention by a health care professional; leading to hospitalization or increased level of care; or prompting evaluation
Type 3
       Type 3a    Overt bleeding plus hemoglobin drop of 3–5 g/dL* (provided hemoglobin drop is related to bleed) 
Any transfusion with overt bleeding
       Type 3b    Overt bleeding plus hemoglobin drop 5 g/dL* (provided hemoglobin drop is related to bleed) 
Cardiac tamponade 
Bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid) 
Bleeding requiring intravenous vasoactive agents
       Type 3c    intracranial bleeding (does not include microbleeds or hemorrhagic transformation, does include intraspinal) 
Subcategories confirmed by autopsy or imaging or lumbar puncture 
intraocular bleed compromising vision
Type 4    Coronary artery bypass graft-related bleeding 
Perioperative intracranial bleeding within 48 hours 
Reoperation after closure of sternotomy for the purpose of controlling bleeding 
Transfusion of 5 U whole blood or packed red blood cells within a 48-hour period† 
Chest tube output 2 L within a 24-hour period
Type 5  Fatal bleeding
       Type 5a  Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious
       Type 5b  Definite fatal bleeding; overt bleeding or autopsy or imaging confirmation
Notes: *Corrected for transfusion (1 U packed red blood cells or 1 U whole blood = 1 g/dL hemoglobin); †cell saver products are not counted.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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severe bleeding, respectively). The corresponding HR for 
six-month mortality were 1.4 (1.2–1.6), 2.1 (1.8–2.4), and 7.5 
(6.1–9.3), respectively. The association between severity of 
bleeding and adverse outcomes remained after adjustment for 
potential confounding factors, including blood transfusions 
and after censoring for CABG and for procedure-related and 
nonprocedure-related bleeds. The results of the study sug-
gested that the GUSTO bleeding classification can identify 
a subset of patients who are at risk for short-term and long-
term adverse events.
Subsequent studies by Eikelboom et al similarly dem-
onstrated a strong temporal and dose-related association 
between bleeding and death in ACS patients without per-
sistent ST segment elevation.10 Data were obtained from 
the OASIS-1, OASIS-2, and CURE trials (OASIS-1 n about 
11,500; OASIS-2 n = 10,141; and CURE n = 12,562). Major 
bleeding was defined in each study as significantly disabling, 
transfusion requirement of 2 units of packed cells, or 
life-threatening. Major bleeding was independently associ-
ated with an increased risk of death during the first 30 days 
(HR 5.37, P  0.0001). In contrast, the HR was weaker 
between 30 days and six months (HR 1.54, P = 0.047). 
Independent baseline predictors of major bleeding included 
older age, diabetes, prior stroke, lower systolic and diastolic 
blood pressures, higher serum creatinine, and ST segment 
changes on electrocardiography. The associations between 
major bleeding were consistent across subgroups according 
to cointerventions during hospitalization (treatment with a 
GPI, unfractionated heparin, low-molecular-weight heparin, 
fibrinolysis, treatment with oral anticoagulants or the need 
for undergoing coronary angiography, CABG, or intra-aortic 
balloon pump). Further analysis demonstrated a dose rela-
tionship between severity of bleeding and increasing risk 
of death (minor less than major less than life-threatening, 
P trend = 0.009). A similar association was observed between 
major bleeding and increased risk of ischemic events (myo-
cardial infarction, stroke) at 30 days and between 30 days 
and six months.
The OASIS-5 trial previously demonstrated that fonda-
parinux was similar to enoxaparin in reducing the risk of 
ischemic events in patients with non-ST elevation ACS at 
nine days while substantially reducing the risk of major 
bleeding.11 More importantly, reduced major bleeding was 
associated with improved long-term morbidity and   mortality. 
In a study to determine the incidence and outcomes after 
bleeding in more than 20,000 patients enrolled in the 
OASIS-5 trial, Budaj et al demonstrated that fondaparinux 
reduced bleeding compared with enoxaparin, but more Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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importantly, the reduced risk of bleeding was associated with 
reduced mortality.12 Of the 57 excess deaths between the two 
groups at 30 days, 66.7% of the deaths were patients in the 
enoxaparin group who experienced bleeding (fatal, major, 
and minor). Similarly, of the 64 excess deaths between the 
two groups at 180 days, 95.3% of the deaths occurred in 
patients from the enoxaparin group who experienced bleed-
ing (fatal, major, and minor). Within each treatment group, 
patients who had more severe bleeding had a higher risk 
of death (major versus minor). Analysis of the relationship 
between major bleeding and outcomes at 30 days in the over-
all patient population revealed a nearly four-fold increase 
in the composite endpoints of death, myocardial infarction, 
or stroke (21.8% versus 6.2%, HR 3.99, 95% confidence 
interval [CI] 3.30–4.82). A similar increase in each of the 
individual components of the composite outcome was also 
observed, ie, death (8.4% versus 2.7%, HR 3.46, 95% CI 
2.60–4.60), myocardial infarction (8.3% versus 3.4%, HR 
4.39, 95% CI 3.45–5.59), and stroke (3.0% versus 0.7%, 
HR 4.66, 95% CI 2.83–7.65, P  0.0001). The magnitude 
of association was attenuated at 180 days but remained sig-
nificant (approximately three-fold increase for the composite 
endpoints and for each individual component, P  0.0001). 
Minor bleeding was also independently associated with an 
increased risk of death, myocardial infarction, and stroke 
as well as the composite endpoints of death/myocardial 
infarction/stroke, at 30 and 180 days. The results of the 
study showed an independent, temporal, and dose-related 
association between bleeding and the composite endpoints of 
death/myocardial infarction/stroke, as well as its individual 
components. Patients who bled were older, more likely to be 
female, more likely to have a history of diabetes, hyperten-
sion, stroke, peripheral vascular disease, heart failure, higher 
serum creatinine, lower baseline hemoglobin, or ST segment 
changes on the electrocardiogram at presentation. In addi-
tion, they were more likely to be treated with antithrombotic 
and antiplatelet medications, and to undergo procedures 
(coronary angiography, PCI, or CABG). The investigators 
concluded that bleeding in patients with ACS is a powerful 
determinant of fatal and nonfatal outcomes. Reducing the 
risk of bleeding using a safer anticoagulation strategy during 
the first nine days is associated with substantial reduction 
in morbidity and mortality.
Although analyses from large-scale, randomized, con-
trolled trials suggest that bleeding independently predicts 
mortality in ACS and PCI, the relative predictive value of 
bleeding compared with other comorbid factors associated 
with mortality remains to be elucidated.
In an analysis of findings from the GRACE registry 
study, Spencer et al demonstrated that the risk of hospi-
tal mortality associated with bleeding was much lower 
than that reported in randomized controlled trials.13 The 
authors speculated that although bleeding may be causally 
related to adverse outcome in the “real-world” setting, it 
is often merely a marker for patients at a higher risk for 
adverse outcomes. Of more than 40,000 patients with 
acute myocardial infarction (53% STEMI, 47% NSTEMI) 
included in the GRACE study, 2.8% experienced major 
bleeding during their index hospitalization. Nearly half 
of these events (49%) occurred on the day of admission 
or on the day after admission. Patients with bleeding were 
more likely to die during hospitalization (HR 1.9, 95% CI 
1.6–2.2) but not after discharge (HR 0.8, 95% CI 0.6–1.0). 
Analysis between bleeding and outcomes among patients 
who bled, regardless of whether fibrinolytic therapy was 
given, similarly demonstrated an increased risk of inhos-
pital death in patients who developed a major bleed. Of the 
5931 patients who received fibrinolytic therapy, 3.1% had 
a major bleeding episode. Their adjusted risk of inhospital 
death compared with those without a bleeding episode 
was three times higher (HR 3.3, 95% CI 2.3–4.7). Among 
patients who bled but did not receive fibrinolytic therapy, 
the risk of inhospital death was attenuated but remained 
significant (HR 1.7, 95% CI 1.4–2.0). Despite the strong 
association between bleeding and inhospital mortality, it is 
noteworthy that, among patients who suffered major bleed-
ing within the first hospital day, mortality rates were higher 
among those who discontinued aspirin, thienopyridines, or 
unfractionated heparin compared with those who bled but 
continued to be treated with these agents after the first day, 
ie, aspirin (OR 7.55, 95% CI 4.43–12.88), thienopyridines 
(OR 8.91, 95% CI 4.39–18.2), and heparin (OR 1.91, 95% 
CI 1.09–3.36). Hence it is speculated that discontinuation 
of antiplatelet and antithrombotic therapies might explain 
in part the increased mortality rates observed in patients 
who experienced bleeding complications.
In a study to determine the predictors of major bleed-
ing and the impact of major bleeding on 30-day outcomes 
including mortality in patients with ACS, Manoukian et al 
demonstrated that major bleeding is a powerful independent 
predictor of 30-day mortality in patients with ACS managed 
invasively.3 Data were obtained from the randomized, open-
labeled, Phase III ACUITY trial.14 Study subjects consisted 
of nearly 14,000 patients with ACS in whom urgent or early 
intervention was planned. Of the 13,819 patients studied, 
4.7% experienced major bleeding. The use of bivalirudin Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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alone compared with unfractionated heparin plus GPI was 
associated with a noninferior rate of composite ischemic 
endpoint (death, myocardial infarction, unplanned revascu-
larization for ischemia) but significantly reduced the rates 
of major bleeding and, hence, net clinical outcome. Patients 
with major bleeding had higher 30-day mortality rates, com-
posite ischemia, and stent thrombosis compared with those 
without major bleeding (P  0.0001 for each analysis). More 
importantly, major bleeding was found to be an independent 
predictor of 30-day mortality (OR 7.55, 95% CI 4.68–12.18, 
P  0.0001). Older age, lower body weight, female gender, 
diabetes, hypertension, anemia, renal insufficiency, elevated 
cardiac biomarkers, and ST segment deviation of 1 mm 
were more frequently observed in patients who experienced 
major bleed. They were also more frequently given a GPI, 
and more likely to undergo PCI rather than CABG, or be 
assigned to medical therapy. Knowledge of these findings 
might be useful to reduce bleeding risk and improve out-
comes in ACS.
It has been suggested that the relative value of bleeding 
in predicting mortality can be assessed by determining the 
overall contribution of bleeding to mortality. Early results 
of the ACUITY trial demonstrated that both major bleeding 
and myocardial infarction were independent predictors of 
30-day mortality. Mehran et al subsequently evaluated the 
risk of each of these events on the magnitude and timing 
of mortality at one-year follow-up.15 Of more than 13,000 
patients with moderate and high-risk ACS enrolled in the 
ACUITY trial, 5.1% had a myocardial infarction and 4.7% 
had a major bleed within 30 days of randomization. Patients 
who had a major bleed had a 3.5-fold increased risk of 
one-year mortality compared with those who did not bleed, 
whereas patients who had a myocardial infarction had a 
3.1-fold increased risk compared with those who did not 
have a myocardial infarction. Although the risk was slightly 
greater for patients who had a major bleed compared with 
those who had a myocardial infarction, it is noteworthy that 
the risk of death in patients who experienced a myocardial 
infarction was time-dependent, with the risk declining rap-
idly after 30 days (HR 17.7, 95% CI 10.8–28.7, day 0–1; 
HR 1.4, 95% CI 0.9–2.1, days 31+). In contrast, the risk of 
death in patients who experienced a major bleed did not vary 
in the first 30 days, and although the risk slightly decreased 
after day 30, it remained fairly steady over time throughout 
one year. The results of the study demonstrated a strong 
association of both major bleeds and myocardial infarction 
with mortality in the first year after ACS. However, myo-
cardial infarction was correlated with a dramatic increase in 
short-term risk, whereas major bleed correlated with a more 
prolonged mortality risk.
The REPLACE-2 trial was the first large-scale ran-
domized, double-blind, active controlled trial comparing 
inhospital major bleeding rates associated with bivalirudin 
and provisional GPI during PCI versus standard practice 
of low-dose heparin plus planned GPI.4 Of 6010 patients 
enrolled in the study, 3.2% experienced major hemorrhage 
as defined by the REPLACE-2 study protocol. Independent 
baseline predictors of major hemorrhage included advanced 
age, female gender, impaired creatinine clearance, and ane-
mia (defined as hemoglobin 13 g/dL in men and 12 g/dL 
in women), whereas independent periprocedural predictive 
factors included treatment with heparin plus GPI, increased 
procedural duration, provisional use of GPI, increased time 
to sheath removal, length of intensive care unit stay, and 
use of an intra-aortic balloon pump. Patients with major 
bleeding compared with those without major bleeding had 
significantly higher rates of mortality at 30 days (5.1% 
versus 0.2%, P  0.001), six months (6.7% versus 1.0%, 
P  0.001), and one year (8.7% versus 1.9%, P  0.0001). 
Multivariate analysis demonstrated that periprocedural major 
bleeding was an independent predictor of one-year mortality 
(OR 2.66, 95% CI 1.44–4.92, P = 0.002).5
In a retrospective analysis to investigate the incidence, 
predictors, and impact of periprocedural bleeding and blood 
transfusion in .10,000 patients undergoing PCI, Kinnaird 
et al demonstrated that major bleeding was an independent 
predictor of inhospital death after PCI (OR 3.5, P = 0.0001) 
but not after one year, whereas transfusion was an indepen-
dent predictor of inhospital and one-year mortality (OR 2.0, 
P  0.002; OR 1.9, P  0.0001).16 Major and minor bleed-
ing were defined by the TIMI criteria, and no bleeding was 
defined as a hematocrit decrease of 10 points with no clini-
cal bleeding. Of the study sample, major bleeding occurred 
in 5.4%, minor bleeding in 12.7%, and no bleeding in 81.9%. 
Patients who experienced bleeding had higher inhospital mor-
tality (7.5% major, 1.8% minor, and 0.6% no bleeding) and 
higher one-year mortality (17.2% versus 9.1% versus 5.5%) 
in a stepwise fashion with bleeding severity. On multivariate 
analysis, the increased mortality rates remained after one 
year for each bleeding category (P  0.001). Patients who 
bled and received transfusions compared with those who did 
not had significantly higher inhospital mortality, regardless 
of their bleeding category (10.6% versus 5.1% for major 
bleeding, 6.8% versus 0.9% for minor bleeding, 10.3% ver-
sus 0.4% for no bleeding; P  0.001 for all comparisons). 
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number of units transfused and one-year mortality (OR 1.47 
per unit transfused, P  0.001). The use of an intra-aortic 
balloon pump (OR 3.0, P  0.0001), procedural hypotension 
(OR 2.9, P  0.001), and age . 80 years (OR 1.9 compared 
with age  50 years, P = 0.001) were the strongest predictors 
for major bleeding.
In a meta-analysis of four randomized clinical trials 
(ISAR-REACT, -SWEET, -SMART-2 , REACT-2) to inves-
tigate the relationship between bleeding (defined according 
to the TIMI criteria) within 30 days post-PCI and one-year 
mortality and to assess the appropriateness of inclusion of 
periprocedural bleeding in a quadruple composite endpoint, 
Ndrepepa et al demonstrated that bleeding in the first 30 days 
after PCI was as strongly and independently associated with 
mortality as the 30-day occurrence of other commonly used 
components of the composite endpoints in PCI studies, 
such as myocardial infarction, urgent revascularization, or 
death.17 Study subjects consisted of .5000 patients with 
a wide range of coronary artery disease (from lower-risk 
patients undergoing elective PCI to higher-risk patients with 
an NSTEMI) who were randomly assigned to receive abcix-
imab after pretreatment with 600 mg clopidogrel or placebo 
as a control. The 30-day occurrence of bleeding (HR 2.96, 
P  0.001), myocardial infarction (HR 2.29, P  0.001), and 
urgent revascularization (HR 2.49, P = 0.019) independently 
predicted one-year mortality. It is noteworthy that not only 
major but minor bleeding was also associated with one-
year mortality (OR 5.00 versus patients without bleeding, 
P  0.001). The results of the study support the appropri-
ateness of including periprocedural bleeding in a quadruple 
composite of primary endpoints to assess outcomes in 
patients undergoing PCI. Overall, patients who died had   
a worse cardiovascular risk profile, including older age 
(74.3 versus 66.3 years), lower body mass index, history of 
diabetes, elevated cardiac enzymes and serum creatinine, 
multivessel disease, and reduced left ventricular function 
(ejection fraction 51.0% versus 59.0%, P  0.001 for each 
variable).
Results from the HORIZONS-AMI consisting of 3602 
STEMI patients undergoing primary PCI who were random-
ized to receive bivalirudin monotherapy and provisional 
GPI or heparin plus GPI demonstrated that bivalirudin 
monotherapy resulted in significantly reduced 30-day rates 
of major bleeding and net adverse clinical events (9.2% 
versus 12.1%; relative risk [RR] 0.76, P = 0.005), compared 
with heparin plus GPI (abciximab or eptifibatide) owing to a 
lower rate of major bleeding (4.9% versus 8.3%, respectively, 
P  0.001).18 Similarly, 30-day rates of death from cardiac 
causes (RR 0.62, P = 0.03) and death from all causes (RR 
0.66, P = 0.047) were lower in the patients who received 
bivalirudin alone, compared with their counterparts treated 
with heparin plus GPI.
The safety and efficacy of bivalirudin monotherapy 
compared with heparin plus GPI were sustained at three-
year follow-up. Three-year rates of all-cause mortality 
(5.9% versus 7.7%, P = 0.03), cardiac mortality (2.9% 
versus 5.1%, P = 0.001), reinfarction (6.2% versus 8.2%, 
P = 0.0001), and major bleeding not related to CABG 
(6.9% versus 10.5%, P = 0.0001) were lower in the biva-
lirudin group compared with the heparin plus GPI-treated 
groups.19,20
Clinical trial acronyms and their full names are provided 
in Table 3. Studies demonstrating the adverse outcomes 
associated with bleeding are summarized in Table 4.
Table 3 Study acronyms and their respective clinical trial full names (in alphabetical order)
Acronyms Clinical trial full names
ACUiTY Acute Catheterization and Urgent intervention Triage Strategy
CRUSADe Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with early implementation 
of the ACC/AHA guidelines
GRACe Global Registry of Acute Coronary events
GUSTO Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries
HORiZONS-AMi Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial infarction
HORiZONS-SwiTCH effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial infarction
OASiS-5 The Fifth Organization to Assess Strategies in Acute ischemic Syndrome
OASiS-6 The Sixth Organization to Assess Strategies in Acute ischemic Syndrome
RePLACe -1 Randomized evaluation in Percutaneous Coronary intervention Linking Angiomax to Reduced Clinical events-1
RePLACe-2 Randomized evaluation in Percutaneous Coronary intervention Linking Angiomax to Reduced Clinical events-2
TiMi Thrombolysis in Myocardial infarction
TRiTON-TiMi 38 Trial to Assess improvement in Therapeutic Outcomes by Optimizing Platelet inhibition with  
Prasugrel-Thrombolysis in Myocardial infarction
RiVAL Radial versus femoral access for coronary angiography and intervention in patients with acute coronary  
syndromesVascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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The association between bleeding and adverse outcomes, 
particularly mortality in patients with ACS and those under-
going PCI, has increasingly been recognized. The difference 
in the incidence of major bleeding and its associated mortality 
rates is likely due in part to the lack of a standard definition 
of bleeding, differences in study design and demographic 
characteristics, and the potential interplay among various 
risk factors. Furthermore, patients with bleeding complica-
tions commonly have significant comorbidities, which may 
independently correlate with the risk of nonfatal and fatal 
adverse outcomes. Despite adjustment for comorbidities, 
statistical modeling may not capture all baseline differences 
in demographic characteristics between patients with and 
those without bleeding. The contributory role of cessation 
of antiplatelet and antithrombotic therapies to the observed 
mortality rates in patients with bleeding complications should 
not be overlooked, and warrants further studies.
Predictive risk factors for bleeding  
in ACS and PCI
Bleeding is the most common noncardiac complication of 
antithrombotic therapy in ACS and PCI. The following sec-
tion discusses various risk stratification models that have been 
developed to predict major bleeding in patients with ACS 
and those undergoing PCI. Study protocol-defined major 
bleeding is summarized in Table 2.
Moscucci et al were among the first to devise a prediction 
rule for identifying patients at higher risk of major bleeding.21 
In an analysis of the GRACE study, consisting of more than 
24,000 patients with ACS, the investigators demonstrated that 
advanced age, female gender, history of bleeding, and renal 
insufficiency were independently associated with a higher 
risk of bleeding (P  0.01). Pharmacological interventions 
including diuretics, inotropic agents, thrombolytic agents, 
GPI receptor blockers, and vasodilators were found to be 
independently associated with an increased risk of bleeding. 
Similarly, the use of right heart catheterization and PCI were 
independently associated with an increased risk of bleeding. 
The predictive factors for major bleeding were similar among 
the subgroups of patients who presented with a STEMI 
(4.8%), NSTEMI (4.7%), or an unstable angina (2.3%) event. 
Further analysis demonstrated that patients with major bleed-
ing had significantly higher inhospital mortality than those 
without major bleeding (18.6% versus 5.1%, P  0.001). 
After adjustment for comorbidities, clinical presentation and 
hospital therapies, major bleeding remained independently 
associated with increased risk of inhospital mortality (OR 
1.64, 95% CI 1.18–2.28).
In an analysis of the CRUSADE Quality Improvement 
Initiative database, Subherwal et al identified eight inde-
pendent baseline predictors of major inhospital bleeding 
among community-treated NSTEMI patients.22 Of the 
89,134 high-risk patients with NSTEMI enrolled in the 
study, 71,277 patients (80%) were randomly assigned to 
the derivation cohort, and 17,857 (20%) to the validation 
cohort. Major bleeding occurred in 9.4% in the derivation 
cohort and 9.6% in the validation cohort (not statistically 
significant for cross-cohort comparisons). Factors inde-
pendently associated with major bleeding on multivariate 
analysis included female gender, history of diabetes, prior 
vascular disease (peripheral vascular disease or stroke), 
heart rate (higher risk per 10 beats per minute increase), 
systolic blood pressure (higher risk with pressures above 
or below 110–180 mmHg range), signs of congestive 
heart failure, baseline hematocrit 36% (versus 36%), 
and creatinine clearance (higher risk per 10 mL/minute 
decrease). The CRUSADE major bleeding model derived 
from the final regression model discriminated patients who 
did and did not have a major bleeding event in both the deri-
vation (c statistic = 0.72) and validation (c statistic = 0.71) 
cohorts. Further analysis demonstrated that the CRUSADE 
bleeding model was similarly able to predict rates of moder-
ate to severe bleeding according to the GUSTO definition 
(c statistic = 0.71).
To quantify the risk for inhospital major bleeding, 
a   CRUSADE bleeding score was derived by assigning 
weighted integers to each independent predictor on the 
basis of its coefficient in the regression model. The bleed-
ing risk was estimated by the sum of the weighted integers 
(range 1–100 points). Similar to the multivariate model, the 
CRUSADE bleeding score had a good ability to discriminate 
between patients who did and did not have a major bleed-
ing event in the derivation (c statistic = 0.71) and validation 
(c statistic = 0.70) cohorts. In the derivation cohort, the rate of 
bleeding increased 10-fold (3% to .30%) between patients 
in the lowest to patients in the highest bleeding scores. 
A similarly increased trend of major bleeding rates were 
seen across the quintile risk groups (3.1% for patients at very 
low risk [score # 20]; 5.5% for patients at low risk [score 
21–30]; 8.6% for patients at moderate risk [score 31–40]; 
11.9% for patients at high risk [score 41–50]; and 19.5% 
for patients at very high risk [score . 50]; Ptrend  0.001). 
Similar results were seen across quintiles of risk groups in the 
validation cohort (Ptrend  0.001). Similar to the CRUSADE 
major bleeding model, the CRUSADE bleeding score had 
good ability to discriminate between patients who did and Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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did not have a major bleeding event in the derivation and 
validation cohorts.
Although the CRUSADE bleeding score model did not 
include postadmission treatments, it demonstrated preserved 
discrimination across treatment subgroups in the derivation 
cohort. The incidence of major bleeding was higher among 
patients who received at least two antithrombotic medica-
tions (n = 50,969) versus patients who received less than two 
antithrombotic medications (n = 5931; 8.2% versus 6.9%). 
The increased bleeding risk persisted in the analysis within 
each bleeding risk quintile (Ptrend  0.001). Furthermore, 
among patients who received at least two antithrombotic 
medications and underwent invasive procedure (catheter-
ization performed, n = 43,492) versus patients who did not 
undergo an invasive procedure, the rate of major inhospital 
bleeding remained higher within each bleeding risk quintile 
(Ptrend  0.001).
Consistent with the findings of Moscucciet et al, Subher-
wal et al demonstrated an association between bleeding and 
inhospital mortality. Patients who experienced a major bleed 
versus those who did not had a higher mortality rate within 
each bleeding risk quintile (2.2% versus 0.2% for those at 
very low risk; 4.4% versus 0.8% for those at low risk; 6.9% 
versus 1.6% for those at moderate risk; 9.2% versus 3.2% 
for those at high risk; 11.0% versus 6.0% for those at very 
high risk, Ptrend  0.0001). A calculation of the CRUSADE 
bleeding score and its associated risk of inhospital major 
bleeding is available at www.crusadebleedingscore.org.
Nikolsky et al used the database from two large random-
ized PCI trials to develop (the REPLACE-2 trial, n = 6002)4 
and validate (the REPLACE-1 trial, n = 1056)23 a prognos-
tic risk score for major bleeding in patients undergoing 
elective or urgent PCI via the femoral approach. Similar 
to the CRUSADE bleeding score, Nikolsky et al found 
that female gender, baseline anemia, and lower creatinine 
clearance (estimated glomerular filtration rate 60 mL/
minute/1.73 m2) were independent predictors of bleeding.24 
Other clinical and procedural variables that were associated 
with increased risk of bleeding in their bleeding risk model 
included age .55 years, administration of low molecular 
weight heparin within 48 hours pre-PCI, use of GPI, and 
intra-aortic balloon pump use. Based on the seven variables 
identified, a risk score was derived by assigning weighted 
integers to each independent predictor, the sum of which 
comprised a total risk score (range 0.9%–22.2%). Stratifica-
tion of the risk score into four groups revealed a stepwise 
increased risk of bleeding with increasing score, with 
the risk of major bleeding varying from 1.0% in patients 
without risk factors to 5.4% in the high-risk patients (risk 
score 10, n = 1563). The discriminatory power of the risk 
model was confirmed in the validation data set (receiving 
operating curve = 0.62). However, it should be noted that 
the REPLACE-2 trial enrolled a highly selective population 
undergoing PCI using the femoral approach, and included 
treatment variables (ie, invasive procedures and antithrom-
botics), which limits its utility for assessment of baseline 
bleeding risk in a community population.
Studies evaluating predictive risk factors for bleeding in 
ACS and PCI have yielded variable results. Nonetheless, risk 
factors can be categorized into nonmodifiable and modifiable 
risks, ie, the former category to identify high-risk individuals, 
and the latter to optimize treatment variables that are associ-
ated with bleeding risks. Commonly reported nonmodifiable 
risk factors include advanced age, female gender, chronic 
kidney disease (renal insufficiency), baseline anemia, prior 
stroke, smaller body weight, history of hypertension or 
diabetes, and baseline ST segment deviation. Commonly 
reported modifiable (or potentially modifiable) risk factors 
include combination therapy with antithrombotic and anti-
platelet agents, particularly GPI, large sheath size, invasive 
procedures (PCI, intra-aortic balloon pump), procedural 
duration, and femoral versus radial access. The CRUSADE 
bleeding score permits assessment of baseline bleeding risk, 
whereas the REPLACE bleeding score permits both base-
line and treatment variable risk stratification. Although the 
  CRUSADE bleeding score model did not include postadmis-
sion treatments, it is conceivable that bleeding risk increases 
with increasing number of risk factors.
Suggested predictive risk factors for bleeding in patients 
with ACS and those undergoing PCI are summarized in 
Figure 1.
Non-modifiable Potentially modifiable Modifiable
• Female gender
• Chronic kidney disease
• Baseline anemia
• Prior stroke  
• Lower body weight
• History of diabetes
• History of HTN
• Baseline ST-segment 
changes
• Combination Rx with 
antithrombotic  & 
antiplatelets
(particularly GPIs)
• Large sheath size
• Invasive procedures 
• Procedure duration 
• Femoral vs radial access
• Fondaparinux
(vs
enoxaparin)*
• Bivalirudin
monotherapy
(vs UFH + GPI)*
• Advanced age
Figure 1 Risk factors for bleeding.
Note: *Discussed under strategies to reduce bleeding.
Abbreviations:  HTN,  hypertension;  UFH,  unfractionated  heparin;  GPis, 
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Mechanisms behind bleeding  
and mortality
There has been ample literature suggesting an association 
between bleeding and mortality in ACS and PCI. Nonetheless, 
because mortality and bleeding have been demonstrated to 
have overlapping risk factors, including age, anemia, history 
of hypertension, renal insufficiency, prior stroke, and baseline 
ST segment changes, the contributory role of bleeding per 
se and mortality remains to be defined. The following sec-
tion discusses the potential mechanisms of the association 
between bleeding and mortality.
The direct hemodynamic effect of massive hemor-
rhage on mortality risk and the causal relationship between 
intracranial bleed with mass effect and mortality appear 
intuitive. However, the causative role of less severe bleed-
ing on mortality remains speculative. Nonetheless, in acute 
bleeding, while increased in neurohormonal levels such as 
norepinephrine, angiotensin, endothelin-1, and vasopressin 
act to maintain blood pressure and regional blood flow, they 
have also been demonstrated to be associated with adverse 
cardiac events.9 In hemorrhagic shock, upregulation of cel-
lular adhesion molecules, such as P-selectin and vascular 
cell adhesion molecule-1, has been suggested to promote 
eccentric left ventricular remodeling, increase diastolic wall 
stress, increase oxygen consumption, and thus exacerbates 
myocardial ischemia and increases mortality.9 Furthermore, 
bleeding can result in reduced oxygen supply and increased 
oxygen demand, the former attributable to anemia and 
reduced tissue perfusion and the latter as a result of stress 
and tachycardia. It is conceivable that the disparity in oxy-
gen supply and demand can lead to coronary ischemia and 
increased mortality.25
In addition to the seemingly direct effect of bleeding 
on mortality, measures to ameliorate bleeding, such as 
discontinuation of antithrombotic therapy, paradoxically 
increases mortality risk. In the GRACE registry study, 
patients with acute myocardial infarction who experienced 
bleeding had a higher frequency of discontinuation of aspirin, 
thienopyridines, and heparin compared with those who did 
not bleed.13 More importantly, Spencer et al demonstrated 
higher inhospital mortality rates in patients who discontin-
ued aspirin, thienopyridines, or unfractionated heparin after 
experiencing major bleeding compared with those who 
continued their anticoagulation therapy despite their bleed-
ing episodes.13 Patients with ACS and those undergoing PCI 
are in a heightened state of thrombosis and platelet activa-
tion. It is conceivable that withholding of antithrombotic 
therapy can result in activation of the coagulation system and 
platelets, which compromises coronary blood flow leading 
to   myocardial damage, reduced left ventricular function, 
and fatal cardiac arrhythmias. Furthermore, activation of 
the coagulation cascade can lead to stent thrombosis and 
nonfatal and fatal cardiac events. Retrospective analysis 
of the Phase III ACUITY trial demonstrated a greater than 
five-fold increase in stent thrombosis among patients who 
experienced major bleeding.3
Acute bleeding may require blood transfusions to replen-
ish plasma volume rapidly and to increase oxygen-carrying 
capacity for tissue oxygenation. However, there has been 
accumulating literature demonstrating an association between 
blood transfusions and increased mortality risk. Results 
from the GUSTO IIb, PURSUIT, and PARAGON B trials 
demonstrated that blood transfusions in the setting of ACS 
were associated with a nearly four-fold increase in the risk of 
death at 30 days.26,27 Transfusion of stored packed red blood 
cells can result in depletion of 2,3-diphosphoglycerate and 
nitric oxide from red blood cells resulting in increased affinity 
of hemoglobin for oxygen and impaired release of oxygen 
at the capillary level, ultimately leading to reduced tissue 
oxygen delivery.28,29 Hence, a transfusion-associated increase 
in hemoglobin concentration is not proportionally associated 
with an increase in tissue oxygenation.30 Blood transfusions 
have also been shown to be associated with an increase 
in the production of proinflammatory cytokines and other 
bioreactive substances that may promote coronary ischemia 
and thrombosis.29,31 Other suggested adverse consequences 
from blood transfusions include exposure to viral pathogens, 
immune suppression, fluid overload, electrolyte imbalance, 
and increased blood viscosity.32 Lastly, acute bleeding may 
necessitate invasive interventions and anesthesia which 
may independently contribute to the increased incidence of 
mortality observed in these patients. Suggested mechanisms 
of the association between bleeding and mortality are sum-
marized in Figure 2.
Bleeding can be classified into two arbitrarily defined 
states, ie, acute, occurring in patients with ACS and those 
undergoing PCI, and chronic, occurring during maintenance 
therapy with anticoagulation. The following section discusses 
suggested strategies to reduce bleeding complications in the 
acute settings. Discussion of strategies to reduce bleeding 
complications in the chronic setting is beyond the scope of 
this article.
Risk stratification
While no single protocol with maximum treatment effi-
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risk assessment assists clinicians to tailor procedures and 
  pharmacotherapy to each individual patient. A risk score 
derived from the REPLACE study demonstrated that the 
risk of protocol-defined major bleeding varies from 1.0% in 
patients without risk factors to greater than 5% in those with 
a risk score .10, whereas the CRUSADE bleeding score 
offers baseline risk stratification.22,23,33
Choice of antiplatelet  
and antithrombotic therapy
Efforts to improve clinical outcomes in patients with 
ACS and those undergoing PCI entail a judicious balance 
between antithrombotic effect and risk of bleeding. Hence, 
unless contraindicated, administration of medications that 
have been shown to ameliorate bleeding risk should be 
considered.
The OASIS-5 trial demonstrated that fondaparinux 
was as effective as enoxaparin in reducing the risk of 
ischemic events, but with a nearly 50% reduction in the 
incidence of major bleeding and a .60% reduction in 
minor bleeding compared with enoxaparin.34 More impor-
tantly, a reduction in the incidence of bleeding has been 
suggested to account for the long-term reduction of death 
in patients treated with fondaparinux compared with their 
enoxaparin-treated counterparts. Results of both OASIS-5 
and OASIS-6 (comparing unfractionated heparin for 
4–48 hours versus fondaparinux 2.5 mg subcutaneously 
daily for up to eight days in a placebo-controlled double-
blind trial in patients with STEMI undergoing PCI) suggest 
that using unfractionated heparin with fondaparinux during 
PCI substantially reduces the risk of catheter   thrombosis 
and related complications, without an increase in clinical 
complications or major bleed.34,35 Nonetheless, it should be 
noted that currently available data do not support a role for 
fondaparinux during PCI for stable or unstable coronary 
artery disease.
Although administration of unfractionated heparin is 
still regarded as the gold standard antithrombotic therapy 
in the early periprocedural period, bivalirudin overcomes 
several limitations of heparin and may be considered as 
an alternative strategy to unfractionated heparin plus GPI, 
particularly in patients at risk for bleeding complications. 
Results of the ACUITY and REPLACE-2 trials demon-
strated that bivalirudin significantly reduced the risk of 
bleeding while maintaining efficacy in reducing ischemic 
events in comparison with heparin plus GPI.3,4 Similarly, 
the HORIZONS-AMI trial demonstrated reduced rates of net 
adverse clinical events and major bleeding with the use of 
bivalirudin monotherapy compared with heparin plus GPI in 
patients with STEMI undergoing PCI.19,36 However, the use 
of bivalirudin is relatively contraindicated in patients with 
chronic total occlusion because there is currently no agent to 
reverse the antithrombotic effect of bivalirudin. Bivalirudin 
should be used with caution in patients without unfractionated 
heparin or clopidogrel pretreatment due to increased risk of 
acute stent thrombosis.
In a recent analysis of the HORIZONS-SWITCH study, 
Dangas et al demonstrated that in patients with STEMI 
Direct
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↑ O2 demand
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(paradoxical ↓ tissue
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Figure 2 Suggested mechanisms of the association between bleeding and mortality (see text for details).
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who received early treatment with unfractionated heparin, 
switching to bivalirudin before primary PCI resulted in 
reduced rates of major bleeding and improved early and late 
cardiac survival.37 Study subjects consisted of 2357 patients 
in the   HORIZONS-AMI trial who received unfractionated 
heparin before study enrollment and were subsequently 
randomly assigned to bivalirudin (switch group, n = 1178) 
or unfractionated heparin plus GPI (control group, n = 1179). 
At 30 days, major bleeding occurred in 7.6% and 12.3% in 
the switch and control groups, respectively, P = 0.0001. 
Furthermore, 30-day rates of cardiac mortality was lower 
in the switch compared with the control groups (1.6% ver-
sus 2.9%, respectively, P = 0.04). Similarly, at two-year 
follow-up, switch patients experienced lower rates of major 
bleeding (P = 0.0003), cardiac mortality (P = 0.04), and 
reinfarction (P = 0.0002) while two-year rates of definite 
or probable stent thrombosis were similar between the two 
treatment groups (switch versus control, 3.1% versus 4.3%, 
respectively, P = 0.17). The results of the study suggested 
that a strategy of switching STEMI patients who received 
early treatment with unfractionated heparin to bivalirudin 
may be safe and effective, resulting in reduced hemorrhagic 
complications and cardiac mortality and enhanced event-free 
survival compared with unfractionated heparin continua-
tion and initiation of GPI. Nonetheless, the investigators 
acknowledged that the results of the HORIZON-SWITCH 
study should be considered exploratory and hypothesis-
generating due to limited statistical power. Further studies 
are needed.
Results of the TRITON-TIMI 38 trial demonstrated 
that patients with ACS and known coronary anatomy who 
received aspirin and prasugrel had a lower risk of ischemic 
event but a greater risk of TIMI major and life-threatening 
bleeding (particularly in those undergoing CABG or those 
with a history of cerebrovascular disease) compared with 
those receiving aspirin and clopidogrel.38,39 Further analysis 
Risk stratification
• Modifiable  & non-modifiable risk factors
• CRUSADE bleeding score (baseline bleeding risk)
• Risk score drawn from the REPLACE trials (risk of bleeding
   varies from 1% in patients with no risk factors to 5.4% in
   those with a risk score ≥10)
• Attention to vascular access
• Use radial (vs femoral) when
   technically feasible
• Consider Bivalirudin monotherapy (vs UFH + GPI) in
   patients @ high risk for bleeding
• Consider short-term prasugrel followed by long-term
   clopidrogel (to maximize ischemic prevention & 
   minimize bleeding risk)
• Consider fondaparinux (vs enoxaparin): similar
   efficacy but ↓ in bleeding risk
Identify high-risk individuals/tailor treatment and
intervention to each individual patient 
Invasive intervention Choice of antiplatelet and antithrombotic
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demonstrated that the majority of ischemic event reduction 
associated with prasugrel occurs during the first 30 days of 
treatment while bleeding events continue to accrue during 
long-term maintenance therapy. Hence, it has been suggested 
that one strategy to minimize bleeding while maximizing 
ischemic protection might involve the early use of prasugrel 
in patients with ACS undergoing PCI, followed by long-term 
therapy with clopidogrel. Such strategy might also reduce 
the rates of bleeding-related discontinuation of therapy, 
which was significantly greater among prasugrel versus 
  clopidogrel-treated patients. The routine recommendation 
of short-term prasugrel followed by long-term clopidogrel 
to maximize treatment efficacy and minimize bleeding risk 
awaits further studies. Nonetheless, it should be noted that 
prasugrel is contraindicated in patients with active pathologi-
cal bleeding, history of stroke or transient ischemic attack, 
and those who will likely require coronary artery bypass 
grafting.
Medication dosages and laboratory 
monitoring
The CRUSADE registry database revealed that over 42% of 
patients with NSTEMI received one or more antithrombotic 
agents above the recommended dosage range.40 Excessive 
dosing and the number of agents administered in excess were 
found to be directly related to the risks of bleeding. It has 
been suggested that proper dosing requires adjustment based 
on body weight and renal function. Meticulous attention to 
appropriate dosing of antithrombotic agents, particularly 
GPI and unfractionated heparin, and close monitoring of 
activated clotting time may reduce bleeding risks. Suggested 
activated clotting time for patients undergoing PCI with and 
without GPI are 200–250 seconds and 300–350 seconds, 
respectively.
Invasive intervention
In addition to manipulating antithrombotic strategies, 
reduction of bleeding risk can also be achieved with careful 
attention to vascular access, using the radial artery approach 
(versus femoral) during cardiac catheterization and PCI 
procedures, and using vascular closure devices post cardiac 
catheterization and post-PCI. However, the use of vascular 
closure devices to reduce vascular bleeding remains contro-
versial, except for the benefit of decreasing time to ambula-
tion and length of hospitalization. Currently, the American 
Heart Association issues a Class III   recommendation of 
use of vascular closure devices for the purpose of reducing 
vascular complications. Nonetheless, the rates of bleeding 
complications or procedural failures or both may be operator-
dependent and the choice of the procedure should be at the 
discretion of the interventional cardiologists.39,41–44 Suggested 
strategies to reduce bleeding complications are summarized 
in Figure 3.
Conclusion
The advent of potent antiplatelet and antithrombin agents 
has resulted in significant improvement in cardiovascular 
outcomes in patients with ACS and those undergoing PCI. 
However, these treatment strategies have led to an increase in 
the risk of bleeding. Such bleeding complications have been 
shown to be associated with myocardial infarction, stroke 
risk, and more importantly mortality. Hence, assessment 
of bleeding risks and implementing pharmacological and 
nonpharmacological measures to reduce bleeding compli-
cations should be an integral part of the management of 
patients with ACS and those undergoing PCI. Appropriate 
dosing of medications should not be overlooked. The judi-
cious balance between antithrombotic effect and bleeding 
risk and the use of the radial approach when technically 
feasible may improve clinical outcomes. Intervention aimed 
at halting the bleeding may paradoxically have a negative 
impact on outcomes, hence management of periprocedural 
bleeding should be individualized. While the association 
between blood transfusions and mortality has not been fully 
elucidated, blood transfusion should only be given after care-
fully weighing the risks and benefits. Lastly, future clinical 
trials should include bleeding as a quadruple primary end-
point, combining death, myocardial infarction, urgent repeat 
revascularization, and bleeding to better assess patients’ 
cardiovascular outcomes.
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